#United States #San Francisco #Clinical Trials #Regeneron Pharmaceuticals #Hagens Berman

Regeneron Pharmaceuticals in Hot Water Over Failed Trial Revelations

In a dramatic turn of events for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), the company is now facing a securities class action lawsuit, igniting concerns among investors and stakeholders. The lawsuit stems from shocking admissions regarding a Phase 3 clinical trial intended for treating patients with melanoma. As news of the trial's failure spread, Regeneron shares plummeted, resulting in a staggering $11 billion loss in market capitalization, and prompting legal action aimed at protecting the interests of aggrieved investors.

The firm spearheading the lawsuit, Hagens Berman, is currently investigating claims against Regeneron. They urge investors who have incurred significant losses to share their experiences. The lawsuit caters to those who acquired Regeneron shares between August 1, 2025, and May 15, 2026.

At the heart of the litigation is the scrutiny of Regeneron's repeated assurances regarding the trial protocol for its cancer therapy, Fianlimab, in conjunction with Libtayo, labelled as a potential game-changer for melanoma treatments. The pivotal aspect of this trial was the primary endpoint centered on progression-free survival (PFS).

The complaint alleges that Regeneron misled its investors by providing false statements and withholding critical information. Key accusations highlight flaws in the trial's preliminary statistical methodology and inadequate differentiation between the treatment and standard therapies. Despite the increasing evidence of the trial's underperformance, the company persisted in projecting optimism about the study's success, even as event rates slowed.

The turning point for investors came on April 29, 2026, when Regeneron disclosed changes made to the trial protocol, raising red flags regarding the true status of the study's progress. This revelation sparked skepticism among analysts about the management's earlier assertions of confidence in achieving the primary endpoint.

Moreover, on May 12, 2026, Regeneron admitted to making these protocol alterations due to sluggish event rates, suggesting that such concerns had existed for nearly half a year prior. The mounting doubts culminated on May 15, 2026, when Regeneron unveiled the disheartening news that the trial had failed to demonstrate statistical significance regarding its primary PFS endpoint.

"Our focus lies in determining whether Regeneron amended the trial protocol without informing investors in a timely manner, thereby misleading them about the true potential of what was labeled as a blockbuster treatment," stated Reed Kathrein, the partner from Hagens Berman leading this investigation.

Investors who sustained substantial losses, as well as individuals possessing non-public information regarding Regeneron, are encouraged to engage in the ongoing investigation. As part of the SEC Whistleblower program, those with relevant knowledge of the situation may also benefit from potential monetary rewards if the information leads to successful recoveries.

Hagens Berman is recognized for its commitment to corporate accountability, having represented clients in various cases that resulted in significant recoveries amounting to over $2.9 billion. Their work reflects a dedication to protecting investor rights, along with ensuring that companies uphold transparent communication standards.

As this situation continues to evolve, Regeneron's shareholders remain anxious about the company's future and the potential implications this lawsuit may impose. For those affected, the upcoming legal proceedings could provide a platform for redress and may hold the company accountable for any misdeeds.

Additional Information

For further updates and potential contributions to the firm's investigation, Regeneron shareholders who believe they've been adversely affected by these developments are encouraged to visit Hagens Berman's website and reach out to their attorneys. Contact information is also available for those wishing to share their insights or seek answers regarding the ongoing legal battle over Regeneron Pharmaceuticals.

Whether the allegations hold water remains to be seen, but this case will undoubtedly shed light on critical issues surrounding pharmaceutical trials and investor rights in the years to come.